Home > Figures & Reports > Annual Results 2007
 
Business Sales
Annual Results 2007
Annual Report 2007
Key Figures 2007
Key Performance Indicators(pdf)
Annual Media Conference
Annual Results 2007
Letter from the Chairman
Roche Group
Half-Year Report 2007
Annual Results 2006
Annual Report 2005
Annual & Sustainability Report 2004
Annual & Sustainability Report 2003
Annual Report 2002
Annual Report 2001
Annual Report 2000
Annual Report 1999
SHE Reports

Annual Results 2007
 

Annual Report 2007  (Business & Finance Report)

Interactive version of the entire Annual Report 2007
 

Business Report

Finance Report




Annual Media Conference

 



IR Conference & Presentations to Investors

- Conference Call in Basel, 30 January 2008
- Presentation in London, 30 January 2008
- Presentation in New York, 1 February 2008
... more ...

 


Letter from the Chairman

Dear Shareholders,
Your company achieved outstanding results again in 2007, despite tougher market conditions. For the seventh straight year the Roche Group’s sales increased by double-digits, advancing 10% to 46 billion Swiss francs. This more than 4 billion Swiss franc increase in sales revenues was all achieved organically. Once again, the Pharmaceuticals Division was the main growth driver. Its sales grew almost twice as fast as the global pharmaceuticals market. The Diagnostics Division maintained its position as the global market leader in in vitro diagnostics, with divisional sales increasing slightly ahead of the market.  ...more ...
 
 


Roche Group: Group results - Outlook - Group strategy

The Roche Group posted record results in 2007. Group sales were up significantly, advancing 10% in local currencies (10% in Swiss francs; 15% in US dollars) to 46.1 billion Swiss francs. This 4.1 billion Swiss franc rise in full-year sales was all organic growth. The Pharmaceuticals Division’s sales increased 11% in local currencies (10% in Swiss francs; 15% in US dollars) to 36.8 billion Swiss francs; this was approximately twice the global market growth rate. Demand remained very strong for the cancer medicines Avastin, Herceptin, MabThera/Rituxan, Tarceva and Xeloda. Combined sales of the division’s oncology products were up 20% for the year, reinforcing Roche’s market leadership in this therapeutic area. Other pharmaceuticals driving growth included Bonviva/ Boniva for osteoporosis, CellCept in transplantation, Pegasys in virology and the ophthalmology medicine Lucentis. The Diagnostics Division strengthened its market leadership with sales totalling 9.3 billion Swiss francs, a 6% increase in local currencies (7% in Swiss francs; 12% in US dollars) over 2006. Professional Diagnostics and Applied Science were the business areas posting the strongest growth.  ... more ...
Deutsche Sprachversion     

English Version     
print this page 30.1.2008 © 1996-2008 F.Hoffmann-La Roche Ltd

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.